Skip to main content
Home
FDA
  • LOG IN
  • Thompson FDA
  • Manage Account
  •  
  • 1.800.677.3789

Main navigation

  • LIBRARY
    • FDA Enforcement Manual
    • Guide to Good Clinical Practice
    • FDA Advertising and Promotion Manual
    • Guide to Medical Device Regulation
    • Guide to U.S. Food Labeling Law
  • MY RESEARCH
  • NEWS
    • All News
    • FDA Intelligence
  • DATABASES
    • FDA Enforcement Database
    • Clinlaw State Database
  • RESOURCES
    • FDA Forms
    • Special Reports
    • Judicial Opinions
    • Interactive Tools
  • AGENCY GUIDANCE
    • Enforcement Guidance
    • Clinical Trials Guidance
    • Advertising and Promotion Guidance
    • Medical Device Guidance
    • Food Labeling Guidance
  • ASK THE EXPERT

Login to the Thompson
FDA Compliance Expert

Enter your FDA username.
Enter the password that accompanies your username.
Forgot password?

Questions? Give us a call! 1-800-677-3789

Advertising & Promotion

  • Apr 15, 2023
    FTC Sends Out Nearly 700 Notices of Penalty Offenses on Substantiating Claims
  • Apr 13, 2023
    District Court Dismisses Case Over Abreva Advertising Claims
  • Apr 5, 2023
    FDA Readies Final Guidance on Quantitative Efficacy and Risk Info in DTC Ads
  • Mar 28, 2023
    District Court Dismisses RICO Case Involving Patient Assistance Program
  • Mar 17, 2023
    ABPI Suspends Novo Nordisk Over Sponsored Course Promoted on LinkedIn
  • Mar 16, 2023
    Interviews with Health Care Influencers Find Resistance to Company Messaging
  • Mar 7, 2023
    Permanent Injunctions Entered Against Three Distributors Over Marketing Claims
  • Feb 28, 2023
    FDA Debars Former Chief Executive and Former Medical Director Over Marketing Claims
  • Feb 22, 2023
    CDRH Issues Warning Letter Over Off-label Promotion
  • Feb 10, 2023
    Studies Reveal That Most DTC Advertising Is for Drugs with Low Added Clinical Benefit
  • More

Good Clinical Practice

  • Jul 26, 2023
    University Receives Determination Letter for Allegedly Not Revising Written IRB Procedures To Reflect Revised Common Rule
  • Jul 18, 2023
    FDA Provides ‘Good Cause’ Reasons for Missing PMR Deadlines
  • Jul 12, 2023
    SEC Charges Former Trial Statistician with Insider Trading
  • Jun 23, 2023
    OHRP Explains Use and Operation of Limited IRB Review
  • Jun 13, 2023
    FDA Debars Two Former Trial Coordinators
  • Jun 11, 2023
    FDA Issues Warning Letters to Two Clinical Investigators
  • Jun 5, 2023
    Number of BIMO Inspection Observations Dips Slightly in FY 2022
  • May 28, 2023
    Draft ICH GCP Guideline Looks To Aid Use of New Technology in Clinical Trials
  • May 14, 2023
    FDA Opens Dialogue on Possible Benefits, Harms From Use of AI/ML in Drug Development
  • May 6, 2023
    FDA: Decentralized Trials Still Need Central Location for Records
  • More

U.S. Food Labeling

  • Oct 27,2022
    FDA Officials Explain Need for ‘Healthy’ Labeling Proposal, FOP Labeling
  • Oct 12,2022
    Poll Results Show Strong Support for MCOOL Labeling for Beef
  • Sep 29,2022
    FDA Proposes Updates to Definition, Nutrient Content Claim for ‘Healthy’
  • Sep 29,2022
    Administration Proposes Labeling Changes as Part of National Food Strategy
  • Sep 16,2022
    District Court Upholds Majority of NBFDS Regulations But Rejects Text Message Disclosure Option
  • Sep 15,2022
    Groups Want FDA To Beef Up Front-of-Package Nutrition Labeling Requirements
  • Sep 1,2022
    Studies Look at Market Effect of Mandated GMO Labeling Under Vermont Law
  • Aug 18,2022
    FDA Finalizes Guidance on Supplements Containing NAC
  • Jul 30,2022
    AMS Proposes Two Additions to List of Bioengineered Foods
  • Jul 21,2022
    Petitioners Ask FSIS To Stop Approving Labels With Animal Raising Claims, Grant Flexibility for Beef Stroganoff Product
  • More

FDA Regulation & Enforcement

  • May 21, 2025
    Device Firm CEO Pleads Guilty to Charge of Making False Statements to CMS Regarding Alleged Kickbacks
  • May 21, 2025
    DOJ Revises Criminal Enforcement Policies To Encourage Self-Disclosure of Corporate Wrongdoing
  • May 20, 2025
    Concerns Over Risk Claims Prompt Untitled Letter for Speaker Deck
  • May 14, 2025
    FDA, HHS Launch Deregulation Initiative, Seek Public Input on Outdated, Unneeded Rules, Guidance
  • May 14, 2025
    Assertio Therapeutics Enters Into $3.6M Settlement To Resolve Off-Label False Claims Allegations
  • May 9, 2025
    Gilead Agrees to $202 Million Settlement Over Speaker Program
  • May 9, 2025
    FDA Extends Proposed FOP Rule Comment Period to July 15
  • May 7, 2025
    FDA Announces Intent To Conduct More Unannounced Inspections at Foreign Manufacturing Facilities
  • May 5, 2025
    House-Senate Bills Look To End DTC Ad Tax Deduction
  • Apr 30, 2025
    State Law Claims Brought by Survivors of Victim of Faulty ICD Dismissed on Preemption Grounds
  • More

Medical Devices

  • Apr 29, 2024
    Final Rule Applies Device Regulatory Requirements to LDTs; Enforcement Discretion To Be Phased Out
  • Apr 24, 2024
    Products Liability Suit Involving Recalled Implanted Defibrillator Implicated in Death Is Dismissed
  • Apr 17, 2024
    Premarket Review Reform, ‘Home as a Health Care Hub’ Are on CDRH’s Innovation Agenda for 2024
  • Apr 17, 2024
    Diagnostic Firm CEO Receives Seven-Year Prison Sentence for $28 Million COVID Test Fraud Scheme
  • Apr 10, 2024
    Court Enters Consent Decree Against Philips Respironics Following Recall of Sleep Therapy Devices
  • Apr 4, 2024
    Failure-To-Warn, Strict Liability, Negligence Claims Involving Class III PMA Device Survive Preemption
  • Mar 27, 2024
    FDA Again Proposes To Ban Electrical Stimulation Devices Intended for Behavioral Treatments
  • Mar 21, 2024
    Device Associations Cautious Following Release of EPA Final Rule on Ethylene Oxide Emissions
  • Mar 14, 2024
    Draft Guidance Outlines FDA’s Expectations for Meeting FDORA Submission Mandates for Cyber Devices
  • Mar 13, 2024
    Jury Returns Verdict Against CEO of Firm That Marketed Neurostimulation Device With Phony Component
  • More

THOMPSON FDA

  • Thompson FDA
  • About Us
  • Manage Account
  • Our Parent Company

COMPLIANCE EXPERT

  • News
  • My Research
  • Our Experts
  •  

RESOURCES

  • FDA Forms
  • Special Reports

HELP

  • Customer Support
  •  
  •  
  •  
  •  

CONTACT

  • headquarter Headquarters
  • contact-number 1.800.677.3789
  • Contact Us
  •  

Copyright © Thompson FDA, a division of CBIS. All rights reserved.

  • Terms
  • Privacy

FDA NEWS
YOU CAN USE

Get instant, free access to the latest news and analysis to keep up with the shifting requirements, recommendations, and expectations of the FDA.

Something went wrong. Please try after some time.